AWKN Stock Overview
A biotechnology company, engages in the research, development, operation, and delivery of psychedelic therapeutics to treat addiction and other mental health conditions in North America and Europe.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Awakn Life Sciences Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.12 |
| 52 Week High | CA$0.34 |
| 52 Week Low | CA$0.055 |
| Beta | 2.4 |
| 11 Month Change | 9.52% |
| 3 Month Change | -47.73% |
| 1 Year Change | -54.90% |
| 33 Year Change | -94.89% |
| 5 Year Change | n/a |
| Change since IPO | -94.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| AWKN | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | -4.2% | 0.8% | -0.3% |
| 1Y | -54.9% | -40.0% | 10.9% |
Return vs Industry: AWKN underperformed the Canadian Biotechs industry which returned -40% over the past year.
Return vs Market: AWKN underperformed the Canadian Market which returned 10.1% over the past year.
Price Volatility
| AWKN volatility | |
|---|---|
| AWKN Average Weekly Movement | 33.0% |
| Biotechs Industry Average Movement | 12.4% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in CA Market | 16.7% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: AWKN's share price has been volatile over the past 3 months.
Volatility Over Time: AWKN's weekly volatility (33%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 6 | Anthony Tennyson | awaknlifesciences.com |
Awakn Life Sciences Corp., a biotechnology company, engages in the research, development, operation, and delivery of psychedelic therapeutics to treat addiction and other mental health conditions in North America and Europe. It develops AWKN-001, a novel medication-assisted treatments (MAT) consisting of racemic ketamine, delivered intravenously, and manualized relapse prevention cognitive behavioural therapy (CBT) which is in phase 3 trials to treat severe Alcohol Use Disorder (AUD); AWKN-002, a novel MAT consisting of a patent pending proprietary S–ketamine oral thin film, and manualized relapse prevention CBT to treat AUD; and MDMA/Zydis, an investigational medicinal product entactogen that acts as a releaser and reuptake inhibitor of serotonin, norepinephrine, and dopamine. The company has a collaboration agreement with the University of Exeter for exploring the use of ketamine-assisted therapy to treat Severe AUD; and with Graft Polymer (UK) PLC to develop chemical entity series programme for trauma-related mental health disorders.
Awakn Life Sciences Corp. Fundamentals Summary
| AWKN fundamental statistics | |
|---|---|
| Market cap | CA$4.64m |
| Earnings (TTM) | -CA$3.75m |
| Revenue (TTM) | CA$96.06k |
48.3x
P/S Ratio-1.2x
P/E RatioIs AWKN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AWKN income statement (TTM) | |
|---|---|
| Revenue | CA$96.06k |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$96.06k |
| Other Expenses | CA$3.85m |
| Earnings | -CA$3.75m |
Last Reported Earnings
Apr 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.093 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,903.90% |
| Debt/Equity Ratio | 0% |
How did AWKN perform over the long term?
See historical performance and comparison